Table 3.
Most frequent related adverse events (≥10% of patients)
| Adverse events | Investigator-determined Maximum CTC Grade, n (%) |
N = 22 n (%) |
|||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | ||
| Diarrhea | 3 (14) | 6 (27) | 3 (14) | – | 12 (55) |
| Fatigue | 6 (27) | 3 (14) | 1 (5) | – | 10 (45) |
| Vomiting | 4 (18) | 4 (18) | – | – | 8 (36) |
| Dry mouth | 6 (27) | – | – | – | 6 (27) |
| Decreased appetite | 3 (14) | 3 (14) | – | – | 6 (27) |
| Dry skin | 4 (18) | 1 (5) | – | – | 5 (23) |
| Hypophosphatemia | 2 (9) | 2 (9) | – | – | 4 (18) |
| Dysgeusia | 4 (18) | – | – | – | 4 (18) |
| Stomatitis | 3 (14) | 1 (5) | – | – | 4 (18) |
| Nausea | 2 (9) | 2 (9) | – | – | 4 (18) |
| Hair color changes | 3 (14) | 1 (5) | – | – | 4 (18) |
| Pyrexia | 3 (14) | – | – | – | 3 (14) |
| ALT increased | 1 (5) | 1 (5) | 1(5) | – | 3 (14) |
| Weight decreased | 1 (5) | 2 (9) | – | – | 3 (14) |
| Alopecia | 3 (14) | – | – | – | 3 (14) |
| Rash | 3 (14) | – | – | – | 3 (14) |
ALT, Alanine aminotransferase